NICE Guidance - March 2024
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of March 2024. This month there are four guidelines and one technology appraisal that impact upon primary care.
The Vitamin B12 deficiency in over 16s: diagnosis and management guideline has been published. It covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.
The COVID-19 rapid guideline: managing COVID-19 guideline has been updated. It covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. The update aligns the therapeutics section with a recently updated Technology Appraisal.
The Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management guideline has been published. It covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.
The Ovarian cancer: identifying and managing familial and genetic risk guideline has been published. It covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
The Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 technology appraisal has been updated. This update includes additional groups eligible for treatment with nirmatrelvir plus ritonavir.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
| « SMC Update - March 2024 | Drug Safety Update - March 2024 » |
Leave a Comment